Plasma p-Tau217 Drop Tied to Better Outcomes on Lecanemab

Published Date: 12 Aug 2026

Patients with Alzheimer's disease show distinct patterns of plasma p-tau217 reduction after starting lecanemab, and those with greater biomarker drops show more favorable cognitive trajectories.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chromatin organization linked to p53 tumor suppression mechanism

2.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

3.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

4.

New protein target discovered for childhood medulloblastomas

5.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot